Search

Your search keyword '"Starý J"' showing total 26 results
Start Over Author "Starý J" Journal leukemia research
26 results on '"Starý J"'

1. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB

Author

Erlacher, M., primary, Yoshimi, A., additional, Stasik, S., additional, Ramamoorthy, S., additional, Lebrecht, D., additional, Noellke, P., additional, Goehring, G., additional, De Haas, V., additional, Starý, J., additional, Masetti, R., additional, Ussowicz, M., additional, Barzilai-Birenboim, S., additional, De Moerloose, B., additional, Kállay, K., additional, Buechner, J., additional, Dworzak, M., additional, Catala, A., additional, Hasle, H., additional, Schmugge, M., additional, Polychronopoulou, S., additional, Boďová, I., additional, Jahnukainen, K., additional, Smith, O., additional, Kavcic, M., additional, Turkiewicz, D., additional, Kjollerstrom, P., additional, Locatelli, F., additional, Wlodarski, M., additional, Thiede, C., additional, Strahm, B., additional, and Niemeyer, C., additional

Published
2023
Full Text
View/download PDF

2. P051 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB

Author

Erlacher, M., Yoshimi, A., Stasik, S., Ramamoorthy, S., Lebrecht, D., Noellke, P., Goehring, G., De Haas, V., Starý, J., Masetti, R., Ussowicz, M., Barzilai-Birenboim, S., De Moerloose, B., Kállay, K., Buechner, J., Dworzak, M., Catala, A., Hasle, H., Schmugge, M., Polychronopoulou, S., Boďová, I., Jahnukainen, K., Smith, O., Kavcic, M., Turkiewicz, D., Kjollerstrom, P., Locatelli, F., Wlodarski, M., Thiede, C., Strahm, B., and Niemeyer, C.

Published
2023
Full Text
View/download PDF

3. P47 - Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH GATA2-RELATED MYELODYSPLASTIC SYNDROME

Author

Bortnick, R., Wlodarski, M., De Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Masetti, R., Stary, J., Turkiewicz, D., Ussowicz, M., Kozyra, E., Albert, M., Bader, P., Bordon, V., Cario, G., Beier, R., Schulte, J., Bresters, D., Mueller, I., Pichler, H., Sedlacek, P., Sauer, M., Zecca, M., Göhring, G., Yoshimi, A., Noellke, P., Erlacher, M., Locatelli, F., Niemeyer, C., and Strahm, B.

Published
2021
Full Text
View/download PDF

4. O27 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: OUTCOMES OF RELAPSED JUVENILE MYELOMONOCYTIC LEUKEMIA: THE ROLE OF SECOND HEMATOPOIETIC STEM CELL TRANSPLANTATION

Author

Yoshimi, A., Vinci, L., Flotho, C., Noellke, P., Erlacher, M., Lebrecht, D., Masetti, R., De Haas, V., De Moerloose, B., Dworzak, M., Hasle, H., Schmugge, M., Stary, J., Turkiewicz, D., Ussowicz, M., Catala, A., Buechner, J., Jahnukainen, K., Kállay, K., Fabri, O., Smith, O., Göhring, G., Locatelli, F., Strahm, B., and Niemeyer, C.

Published
2021
Full Text
View/download PDF

5. O05 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: SOMATIC GENETIC RESCUE IN SAMD9/SAMD9L MDS PREDISPOSITION SYNDROMES

Author

Sahoo, S., Pastor, V., Goodings, C., Noellke, P., Dworzak, M., Stary, J., Locatelli, F., Masetti, R., Schmugge, M., De Moerloose, B., Catala, A., Kállay, K., Turkiewicz, D., Hasle, H., Buechner, J., Jahnukainen, K., Ussowicz, M., Polychronopoulou, S., Smith, O., Fabri, O., Barzilai, S., De Haas, V., Baumann, I., Schwarz-Furlan, S., Göhring, G., Yoshimi, A., Flotho, C., Strahm, B., Erlacher, M., Niemeyer, C., and Wlodarski, M.

Published
2021
Full Text
View/download PDF

7. 233 IER3 in childhood myelodysplastic syndrome

Author

de Vries, A., Zwaan, M., de Haas, V., Hasle, H., Locatelli, F., de Moerloose, B., Polychronopoulou, S., Stary, J., Schmugge-Liner, M., Zecca, M., Beverloo, B., Niemeyer, C., Pieters, R., and van den Heuvel-Eibrink, M.

Published
2011
Full Text
View/download PDF

23. The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study.

Author

de Winter DTC, Langerak AW, Te Marvelde J, Dworzak MN, De Moerloose B, Starý J, Locatelli F, Hasle H, de Vries ACH, Schmugge M, Niemeyer CM, van den Heuvel-Eibrink MM, and van der Velden VHJ

Subjects
Adolescent, Anemia, Refractory etiology, Child, Child, Preschool, Female, Follow-Up Studies, Hemoglobinuria, Paroxysmal etiology, Humans, Infant, Male, Pancytopenia etiology, Prognosis, Retrospective Studies, Anemia, Refractory pathology, Hemoglobinuria, Paroxysmal pathology, Myelodysplastic Syndromes complications, Pancytopenia pathology, Receptors, Antigen, T-Cell, alpha-beta genetics
Published
2021
Full Text
View/download PDF

24. Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML.

Author

Moravcová J, Nádvorníková S, Zmeková V, Michalová K, Brezinová J, Lukásová M, Vítek A, Hrabánek J, Gasová Z, Sedlácek P, and Starý J

Subjects
Adolescent, Adult, Child, Combined Modality Therapy, Female, Fusion Proteins, bcr-abl genetics, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Molecular Diagnostic Techniques, RNA, Messenger analysis, Recurrence, Remission Induction, Retrospective Studies, Reverse Transcriptase Polymerase Chain Reaction, Time Factors, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Lymphocyte Transfusion
Abstract

We monitored DLI treatment of 13 post-SCT relapses using quantitative competitive (QC) RT-PCR for BCR-ABL (sensitivity 10(-5)) and compared responses to DLI alone and DLI in combination with interferon-alpha (IFN). Ten relapses (one blast crisis, five cytogenetic and four molecular) were treated with DLI+IFN, three relapses (one cytogenetic, two molecular) were treated with DLI alone. Except the patient treated in blast crisis, who died, all the patients treated with DLI+IFN achieved complete molecular remission, with the median time interval of 3.9 months (range 0.25-10.5 months). None of the three patients treated with DLI alone have achieved complete molecular remission up to now, i.e. 32, 45, and 50 months after DLI. However, in all of them some decrease of BCR-ABL transcript level was detected. Although the retrospective analyses did not confirm that IFN improved the response to DLI, our results based on sensitive molecular monitoring suggest that DLI effect, at least in some patients, is supported by IFN administration.

Published
2003
Full Text
View/download PDF

25. Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes.

Author

Krsková-Honzátková L, Cermák J, Sajdová J, Starý J, Sedlácek P, and Sieglová Z

Subjects
Adolescent, Adult, Aged, Anemia, Refractory, with Excess of Blasts pathology, Base Pair Mismatch, Child, Child, Preschool, Chromosomes, Human, Pair 11 genetics, CpG Islands, DNA Methylation, DNA Repair genetics, Female, Follow-Up Studies, Genes, Tumor Suppressor, Humans, Infant, Leukemia, Myeloid pathology, Longitudinal Studies, Male, Microsatellite Repeats, Middle Aged, Polymorphism, Genetic, Tandem Repeat Sequences, Telomere genetics, Anemia, Refractory, with Excess of Blasts genetics, Leukemia, Myeloid genetics, Loss of Heterozygosity
Abstract

Screening for loss of heterozygosity (LOH) of the panel of 18 highly polymorphic microsatellite markers, especially from the region 11p15, was carried out on 154 samples from 26 patients with acute myeloid leukemia and eight with myelodysplastic syndromes (MDS). LOH was detected at the majority (72%) of the loci tested: 47% of informative patients displayed LOH for at least one of the microsatellite locus from the region 11p15 and 23.5% of patients displayed LOH among the other markers tested within the study. A longitudinal follow-up of patients showed a remarkable heterogeneity of LOH appearance and its persistance during the course of the disease suggesting an intratumor clonal heterogeneity, or alternatively, presence of LOH in more than one cell clone. The data revealed two regions of high loss of one allele in 11p15.5, defined by markers D11S1363 and D11S1338, indicating that LOH at the subtelomeric region of the short arm of chromosome 11 is a much common event in hematological malignancies than it was previously reported.

Published
2001
Full Text
View/download PDF

26. Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy.

Author

Formánková R, Honzátková L, Moravcová J, Sieglová Z, Dvoráková R, Nádvorníková S, Vítek A, Lukásová M, Starý J, and Brdicka R

Subjects
Adolescent, Adult, Child, Chimera, Disease-Free Survival, Fusion Proteins, bcr-abl genetics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Middle Aged, Neoplasm, Residual, Prospective Studies, Recurrence, Bone Marrow Transplantation, Immunotherapy, Adoptive, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy
Abstract

In the prospective study, we examined hematopoietic mixed chimerism (using polymerase chain reaction (PCR) of variable number of tandem repeat-VNTR sequences) and minimal residual disease (MRD) status (using qualitative and in the case of positivity quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for the BCR/ABL fusion mRNA) in serial peripheral blood samples taken from 25 patients after bone marrow transplantation (BMT) for chronic myeloid leukemia (CML). Increasing mixed chimerism in correlation with increasing signal of MRD was detected in 10 patients. In two patients mixed chimera status and BCR/ABL rearrangement led to hematologic relapse, in five patients molecular relapse was followed by reappearance of Ph chromosome and three patients developed molecular relapse only. Adoptive immunotherapy-donor lymphocyte infusion (DLI), interferon (INF) and discontinuation of post-transplant immunosupression-separately or in different combinations was used in nine patients with molecular, cytogenetic or hematologic relapse of CML. The results demonstrate that significant response at the molecular level can be achieved for a majority of CML patients and that using of all forms of adoptive immunotherapy controlled by MC and MRD is more efficient in patients treated in early molecular relapse-with minimal disease burdens.

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results